Valeant Pharmaceuticals North America LLC
Valeant Pharmaceuticals North America LLC, commonly referred to as Valeant, is a prominent player in the pharmaceutical industry, headquartered in the United States. Founded in 1960, the company has established a strong presence across North America, focusing on specialty pharmaceuticals and over-the-counter products. Valeant is renowned for its diverse portfolio, which includes dermatology, ophthalmology, and neurology products, setting it apart through innovative formulations and targeted therapies. The company has achieved significant milestones, including strategic acquisitions that have bolstered its market position and expanded its product offerings. With a commitment to addressing unmet medical needs, Valeant continues to make strides in the healthcare sector, solidifying its reputation as a leader in the pharmaceutical landscape.
DitchCarbon Score
How does Valeant Pharmaceuticals North America LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Valeant Pharmaceuticals North America LLC's score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Valeant Pharmaceuticals North America LLC's reported carbon emissions
Valeant Pharmaceuticals North America LLC, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of reported figures. The company is classified as a current subsidiary and inherits its emissions data from its parent organisation, but no specific emissions metrics or reduction targets have been disclosed. In terms of climate commitments, Valeant Pharmaceuticals has not outlined any specific reduction initiatives or targets, such as those set by the Science Based Targets initiative (SBTi). The lack of documented climate pledges or reduction strategies suggests that the company may still be in the early stages of developing a comprehensive sustainability framework. As a subsidiary, Valeant's climate performance and commitments may be influenced by the broader strategies of its parent company. However, without specific data or initiatives reported, it is challenging to assess the company's current impact on climate change or its future commitments in this area.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Valeant Pharmaceuticals North America LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
